By Dinesh Nair, Katie Roof and Angelica Peebles | Bloomberg Thousand Oaks-based Amgen agreed to buy Horizon Therapeutics Plc for about $27.8 billion in its biggest-ever acquisition, deepening its commitment to treatments for autoimmune, inflammatory and rare diseases. Amgen will pay $116.50 a share in cash, the companies said in
The post Amgen in Thousand Oaks buying Horizon Therapeutics for $28 billion appeared first on L.A. FOCUS NEWSPAPER.
